Mikhail Blagosklonny, the Individual behind Revolution of anti-aging drugs

Mikhail Blagosklonny is a former professor of oncology in the New York’s Roswell Park Cancer Institute. He studied cancer and aging. Mikhail obtained both his Ph.D. in experimental medicine and an M.D. in medicine from St. Peterburg’s First Pavlov State Medical University.

In 2002, Mikhail Blagosklonny became a higher-ranking scientist at Ordway Research Institute in Albany, New York. He retained this position until he became an oncology professor at the Roswell Park Institute of Cancer in 2009. Previously, he worked as an associate professor of medicine at the New York Medical College.

Mikhail’s focal point in research targets cancer therapies which shield other cells from possible damage. His works vary from molecular and cellular biology to clinical examination such as oncogenes and tumor restrainers, transduction of signal, apoptosis, mitosis, and cycle in a cell.

The anticancer therapy measure taken emphasizes on translating fundamental science to a new anticancer strategy that includes venturing into the exploitation and cycling of cells affected by cancer in addition to resistance drugs to ensure healthy cancer cells protected in the best environmental conditions selected in the body. Follow Mikhail on Google Scholar

Mikhail Blagosklonny has stretched out to reach and try other sophisticated but reliable approaches to diseases related to age and of course aging itself. The scientist tried and tested so many ways to make his long-time dream come to reality. In spite of previous setbacks here and there in his quest to provide sustainable drugs on anti-aging, Mikhail Blagosklonny was able to discover a drug called rapamycin which its use began in 2006.

Apart from researching and identifying anti-aging drugs, Mikhail Blagosklonny authored a theory of aging referred to as hyperfunction theory in addition to anti-cancer approaches referred to as chemotherapeutic engineering and cryotherapy in cells. This kind of works a supported the global understanding of cancer and age-related ailments to a whole new dimension.

Besides publishing close to 300 research articles, reviews and chapters of books, Mikhail is also the Founder and Chief Editor of Cell Cycle. He is the founding partner of Aging, Oncosceince, and Oncotarget. Also, he worked as an Associated Senior Editor for Cancer research on cell destruction and differentiation among many others.

Mikhail Blagosklonny is more famous for what he advocates about the usage of Rapamycin, the cancer drug he developed to help patients prolong their lives. He has done extensive research on the drug to an extent in which the drug was a first anti-aging drug assistant around the world. Mikhail developed hard work and persistence that saw him raise through various ranks to the highest level of appointment. He is consistently improving and diversifying his publications and reaching a wider range of readers than when he began. Visit classroomvoices.org to read more about Mikhail.